Finally, it has been shown that GAS5 can improve the therapeutic resistance of HER2-positive breast cancer to trastuzumab, suggesting that GAS5 can be used as a novel prognostic indicator and candidate drug target for HER2-positive breast cancer and can improve the effect of treatment on trastuzumab-resistant patients. This evidence concerns the gene ERBB2 and breast carcinoma.